» Articles » PMID: 27749922

Genome-Wide Transcriptome Analysis of CD36 Overexpression in HepG2.2.15 Cells to Explore Its Regulatory Role in Metabolism and the Hepatitis B Virus Life Cycle

Overview
Journal PLoS One
Date 2016 Oct 18
PMID 27749922
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatitis B virus (HBV) is a hepatocyte-specific DNA virus whose gene expression and replication are closely associated with hepatic metabolic processes. Thus, a potential anti-viral strategy is to target the host metabolic factors necessary for HBV gene expression and replication. Recent studies revealed that fatty acid translocase CD36 is involved in the replication, assembly, storage, and secretion of certain viruses, such as hepatitis C virus (HCV) and human immunodeficiency virus (HIV). However, the relationship between CD36 and the HBV life cycle remains unclear. Here, we showed, for the first time, that increased CD36 expression enhances HBV replication in HepG2.2.15 cells. To understand the underlying molecular basis, we performed genome-wide sequencing of the mRNA from HepG2.2.15-CD36 overexpression (CD36OE) cells and HepG2.2.15-vector cells using RNA Sequencing (RNA-seq) technology to analyze the differential transcriptomic profile. Our results identified 141 differentially expressed genes (DEGs) related to CD36 overexpression, including 79 upregulated genes and 62 downregulated genes. Gene ontology and KEGG pathway analysis revealed that some of the DEGs were involved in various metabolic processes and the HBV life cycle. The reliability of the RNA-Seq data was confirmed by qPCR analysis. Our findings provide clues to build a link between CD36, host metabolism and the HBV life cycle and identified areas that require further investigation.

Citing Articles

CD36 in liver diseases.

Liu Y, Yin W Hepatol Commun. 2025; 9(1.

PMID: 39774047 PMC: 11717518. DOI: 10.1097/HC9.0000000000000623.


FABP4 Controls Fat Mass Expandability (Adipocyte Size and Number) through Inhibition of CD36/SR-B2 Signalling.

Berger E, Geloen A Int J Mol Sci. 2023; 24(2).

PMID: 36674544 PMC: 9867004. DOI: 10.3390/ijms24021032.


Circulating soluble CD36 as a novel biomarker for progression and prognosis of HBV-related liver diseases.

Cai C, Xiao A, Luo X, Zheng E, Li Y, Lei Y Front Microbiol. 2022; 13:1039614.

PMID: 36406414 PMC: 9667018. DOI: 10.3389/fmicb.2022.1039614.


Interplay between Lipid Metabolism, Lipid Droplets, and DNA Virus Infections.

Farias M, Diethelm-Varela B, Navarro A, Kalergis A, Gonzalez P Cells. 2022; 11(14).

PMID: 35883666 PMC: 9324743. DOI: 10.3390/cells11142224.


Role of CYP4F2 as a novel biomarker regulating malignant phenotypes of liver cancer cells via the Nrf2 signaling axis.

Wan S, Pan Q, Yang G, Kuang J, Luo S Oncol Lett. 2020; 20(4):13.

PMID: 32774486 PMC: 7405372. DOI: 10.3892/ol.2020.11874.


References
1.
Ouyang Y, Guo J, Lin C, Lin J, Cao Y, Zhang Y . Transcriptomic analysis of the effects of Toll-like receptor 4 and its ligands on the gene expression network of hepatic stellate cells. Fibrogenesis Tissue Repair. 2016; 9:2. PMC: 4759739. DOI: 10.1186/s13069-016-0039-z. View

2.
Lucifora J, Protzer U . Attacking hepatitis B virus cccDNA--The holy grail to hepatitis B cure. J Hepatol. 2016; 64(1 Suppl):S41-S48. DOI: 10.1016/j.jhep.2016.02.009. View

3.
Jarcuska P, Janicko M, Kruzliak P, Novak M, Veseliny E, Fedacko J . Hepatitis B virus infection in patients with metabolic syndrome: a complicated relationship. Results of a population based study. Eur J Intern Med. 2014; 25(3):286-91. DOI: 10.1016/j.ejim.2014.01.006. View

4.
Miquilena-Colina M, Lima-Cabello E, Sanchez-Campos S, Garcia-Mediavilla M, Fernandez-Bermejo M, Lozano-Rodriguez T . Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C. Gut. 2011; 60(10):1394-402. DOI: 10.1136/gut.2010.222844. View

5.
Dong Y, Pike A, Mackenzie A, McClenaghan C, Aryal P, Dong L . K2P channel gating mechanisms revealed by structures of TREK-2 and a complex with Prozac. Science. 2015; 347(6227):1256-9. PMC: 6034649. DOI: 10.1126/science.1261512. View